Hong Wan
About
Hong Wan is a scholar working on Infectious Diseases, Epidemiology and Virology.
According to data from OpenAlex, Hong Wan has authored 61 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Infectious Diseases, 18 papers in Epidemiology and 17 papers in Virology. Recurrent topics in Hong Wan's work include HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (17 papers) and Cytomegalovirus and herpesvirus research (9 papers). Hong Wan is often cited by papers focused on HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (17 papers) and Cytomegalovirus and herpesvirus research (9 papers). Hong Wan collaborates with scholars based in United States, Germany and China. Hong Wan's co-authors include Hedy Teppler, Randi Y. Leavitt, Michael D. Miller, Bach‐Yen Nguyen, Peter Sklar, Jeffrey L. Lennox, Mark J. DiNubile, Edwin DeJesus, Anthony Rodgers and Martin Markowitz and has published in prestigious journals such as Journal of Clinical Investigation, Annals of Internal Medicine and PLoS ONE.
In The Last Decade
Hong Wan
55 papers receiving 2.0k citations
Peers
Hong Wan
Jennifer R. King United States
Catherine L. Cherry Australia
Ned Sacktor United States
Pasiri Sithinamsuwan Thailand
Beau K. Nakamoto United States
Gayle Cocita Baldwin United States
Mariana Gerschenson United States
Gildon N. Beall United States
Aylin Yilmaz Sweden
Kunling Wu United States
Citations per year, relative to Hong Wan Hong Wan (= 1×)
peers
Jennifer R. King
Countries citing papers authored by Hong Wan
Since
Specialization
Citations
This map shows the geographic impact of Hong Wan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hong Wan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hong Wan more than expected).
Fields of papers citing papers by Hong Wan
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hong Wan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hong Wan. The network helps show where Hong Wan may publish in the future.
Co-authorship network of co-authors of Hong Wan
This figure shows the co-authorship network connecting the top 25 collaborators of Hong Wan. A scholar is included among the top collaborators of Hong Wan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hong Wan. Hong Wan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chawla, Akshita, Ruthie Birger, Brian M. Maas, et al.. (2025). Comparison of Molnupiravir Exposure‐Response Relationships for Virology Response and Mechanism of Action Biomarkers With Clinical Outcomes in Treatment of COVID ‐19. Clinical and Translational Science. 18(4). e70184–e70184.
2.
Chawla, Akshita, Ruthie Birger, Hong Wan, et al.. (2023). Factors Influencing COVID ‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes. Clinical Pharmacology & Therapeutics. 113(6). 1337–1345.
3.
Chung, Hyun Cheol, Kyungwon Lee, Justin F. Gainor, et al.. (2021). SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer. Annals of Oncology. 32. S215–S216.
4.
Golan, Yoav, Yuexin Tang, Shahrul Mt‐Isa, et al.. (2021). Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial. PharmacoEconomics - Open. 5(3). 469–473.
5.
Duke, Elizabeth R., Brian D. Williamson, Bhavesh Borate, et al.. (2020). CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. Journal of Clinical Investigation. 131(1).
6.
Marty, Francisco M., Per Ljungman, Roy F. Chemaly, et al.. (2019). Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. American Journal of Transplantation. 20(6). 1703–1711.
7.
Fazio, Sergio, David Robertson, Tenshang Joh, et al.. (2017). Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high‐dose statin. Cardiovascular Therapeutics. 36(1).
8.
Gumbiner, Barry, Tenshang Joh, Liang Hong, et al.. (2017). The effects of single‐ and multiple‐dose administration of bococizumab (RN 316/PF ‐04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: Results from four phase I studies. Cardiovascular Therapeutics. 36(1).
9.
Wan, Hong, et al.. (2017). Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition with Bococizumab on Lipoprotein Particles in Hypercholesterolemic Subjects. Clinical Therapeutics. 39(11). 2243–2259.e5.
10.
Smith, William B., et al.. (2016). Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clinical Autonomic Research. 26(4). 269–277.
11.
Ureña‐Torres, Pablo, et al.. (2014). Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. BMC Nephrology. 15(1). 71–71.
12.
Parra, Mario A., Jane Lonie, Hong Wan, et al.. (2013). Medial temporal lobe function during emotional memory in early Alzheimer’s disease, mild cognitive impairment and healthy ageing: an fMRI study. BMC Psychiatry. 13(1). 76–76.
13.
Sande, Tonje A., Angela Scott, Barry Laird, et al.. (2013). The characteristics of physical activity and gait in patients receiving radiotherapy in cancer induced bone pain. Radiotherapy and Oncology. 111(1). 18–24.
14.
Eron, Joseph J., David A. Cooper, Roy T. Steigbigel, et al.. (2013). Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. The Lancet Infectious Diseases. 13(7). 587–596.
15.
DeJesus, Edwin, Jürgen K. Rockstroh, Jeffrey L. Lennox, et al.. (2012). Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK. HIV Clinical Trials. 13(4). 228–232.
16.
Teppler, Hedy, Deborah D. Brown, Randi Y. Leavitt, et al.. (2011). Long-Term Safety from the Raltegravir Clinical Development Program. Current HIV Research. 9(1). 40–53.
17.
Rockstroh, Jürgen K., Jeffrey L. Lennox, Edwin DeJesus, et al.. (2011). Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1–Infected Patients: 156-Week Results From STARTMRK. Clinical Infectious Diseases. 53(8). 807–816.
18.
Lennox, Jeffrey L., Edwin DeJesus, Daniel S Berger, et al.. (2010). Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses. JAIDS Journal of Acquired Immune Deficiency Syndromes. 55(1). 39–48.
19.
Gatell, José M., Christine Katlama, Beatriz Grinsztejn, et al.. (2010). Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 53(4). 456–463.
20.
Whalley, Heather C., James McKirdy, Liana Romaniuk, et al.. (2009). Functional imaging of emotional memory in bipolar disorder and schizophrenia. Bipolar Disorders. 11(8). 840–856.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jennifer R. King Breakdown of academic impact, for papers by Catherine L. Cherry Breakdown of academic impact, for papers by Ned Sacktor Breakdown of academic impact, for papers by Pasiri Sithinamsuwan Breakdown of academic impact, for papers by Beau K. Nakamoto Breakdown of academic impact, for papers by Gayle Cocita Baldwin Breakdown of academic impact, for papers by Mariana Gerschenson Breakdown of academic impact, for papers by Gildon N. Beall Breakdown of academic impact, for papers by Aylin Yilmaz Breakdown of academic impact, for papers by Kunling Wu